Durvalumab vs Tagitanlimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-L1 · full Non-Small Cell Lung Cancer pipeline

Durvalumab

Marketed by AstraZeneca and partners

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT02125461 · Phase 3 · completed

Patients were randomly assigned in a 2:1 ratio and quadruple-blinded to durvalumab or matching placebo, with 476 receiving durvalumab and 237 placebo. The prespecified primary clinical endpoints were met: progression-free survival was 16.8 versus 5.6 months (HR 0.52, p<0.0001), and overall survival also favored durvalumab (HR 0.68, p=0.00251).

Next expected readout: December 2026 · NCT05000710 (registry estimate)

Reported efficacy

Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.); Overall Survival (From baseline until death due to any cause. Assessed until 22 Mar 2018 DCO; up to a maximum of approximately 4 years.): Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8) (met)

Result source: NCT02125461

Tagitanlimab

Marketed by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 2 in Non-Small Cell Lung Cancermonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT07108816 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDurvalumabTagitanlimab
PFS, median16.8 vs 5.6+11.2 vs placebon 476NCT02125461
24 other results
—Not reported
OS, median11.7 vs 8.7vs SoCn 62NCT02352948
20 other results
—Not reported
ORR60.7% vs 60.6%+0.1 vs placebon 219NCT03519971
10 other results
  • 35.5% vs 6.8% n 62 · Phase 3 · secondary NCT02352948
  • 14.9% vs 6.8% n 174 · Phase 3 · secondary NCT02352948
  • 15.4% vs 6.8% n 117 · Phase 3 · secondary NCT02352948
  • 67.6% vs 64.5% n 287 · Phase 3 · secondary NCT04026412
  • 72.2% vs 64.5% n 320 · Phase 3 · secondary NCT04026412
  • 61.3% vs 57.9% n 287 · Phase 3 · secondary NCT04026412
  • 63.1% vs 57.9% n 320 · Phase 3 · secondary NCT04026412
  • 35% vs 23.9% wk 16 · n 60 · Phase 2 · primary NCT03822351
  • 40.3% vs 23.9% wk 16 · n 62 · Phase 2 · primary NCT03822351
  • 58.1% n 62 · Phase 2 · secondary NCT02572843
—Not reported
Duration of response, median30.7 vs 18.6+12.1 vs placebon 133NCT03519971
17 other results
—Not reported

PFS, median

Durvalumab
16.8 vs 5.6+11.2 vs placebon 476NCT02125461
24 other results
Tagitanlimab
—Not reported

OS, median

Durvalumab
11.7 vs 8.7vs SoCn 62NCT02352948
20 other results
Tagitanlimab
—Not reported

ORR

Durvalumab
60.7% vs 60.6%+0.1 vs placebon 219NCT03519971
10 other results
  • 35.5% vs 6.8% n 62 · Phase 3 · secondary NCT02352948
  • 14.9% vs 6.8% n 174 · Phase 3 · secondary NCT02352948
  • 15.4% vs 6.8% n 117 · Phase 3 · secondary NCT02352948
  • 67.6% vs 64.5% n 287 · Phase 3 · secondary NCT04026412
  • 72.2% vs 64.5% n 320 · Phase 3 · secondary NCT04026412
  • 61.3% vs 57.9% n 287 · Phase 3 · secondary NCT04026412
  • 63.1% vs 57.9% n 320 · Phase 3 · secondary NCT04026412
  • 35% vs 23.9% wk 16 · n 60 · Phase 2 · primary NCT03822351
  • 40.3% vs 23.9% wk 16 · n 62 · Phase 2 · primary NCT03822351
  • 58.1% n 62 · Phase 2 · secondary NCT02572843
Tagitanlimab
—Not reported

Duration of response, median

Durvalumab
30.7 vs 18.6+12.1 vs placebon 133NCT03519971
17 other results
Tagitanlimab
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Tagitanlimab: no structured comparison results are available for Non-Small Cell Lung Cancer.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Durvalumab: 4 of 4 rows · Tagitanlimab: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDurvalumab
Dropout rate
62.6%a
NCT02125461 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 34 more results
79%Sub-study A: Durvalumab
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
75.2%Sub-study B: Durvalumab
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
74.1%Sub-study B: Durvalumab+Tremelimum
NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
n/a: no completion milestone
NCT03519971 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
76.3%
NCT03164616 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
31%
NCT04416633 · Phase 4 · registry result, not featured evidence
64.1%Arm A:Nivo + CCRT/Nivo + Ipi
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
56.9%Arm B: Nivo + CCRT/Nivo
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
100%
NCT04642469 · Phase 3 · registry result, not featured evidence
26.7%
NCT04385368 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort 1 (EGFR/ALK+)
NCT02087423 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort 2
NCT02087423 · Phase 2 · registry result, not featured evidence
—Cohort 3 (TC >=90%)
NCT02087423 · Phase 2 · registry result, not featured evidence
0%Durvalumab Cohort A: Standard Radi
NCT04249362 · Phase 2 · registry result, not featured evidence
0%Durvaumab Cohort B: Palliative Rad
NCT04249362 · Phase 2 · registry result, not featured evidence
90%
NCT04003246 · Phase 2 · registry result, not featured evidence
1.5%
NCT02572843 · Phase 2 · registry result, not featured evidence
51.7%Arm A (Durvalumab + Oleclumab)
NCT03822351 · Phase 2 · registry result, not featured evidence · combination
51.6%Arm B (Durvalumab + Monalizumab)
NCT03822351 · Phase 2 · registry result, not featured evidence · combination
—Durvalumab + Monalizumab
NCT03822351 · Phase 2 · registry result, not featured evidence · combination
—Durvalumab + Oleclumab
NCT03822351 · Phase 2 · registry result, not featured evidence · combination
—Durvalumab ECOG PS 0 or 1
NCT03693300 · Phase 2 · registry result, not featured evidence
66.7%Durvalumab ECOG PS 2
NCT03693300 · Phase 2 · registry result, not featured evidence
13.3%Arm 1 (Durvalumab Monotherapy)
NCT02904954 · Phase 2 · registry result, not featured evidence · monotherapy
13.3%Arm 2 (Durvalumab Plus SBRT)
NCT02904954 · Phase 2 · registry result, not featured evidence · combination
0%
NCT02879617 · Phase 2 · registry result, not featured evidence
3.7%1500 mg
NCT03794544 · Phase 2 · registry result, not featured evidence
6.3%1500 mg + 200 mg
NCT03794544 · Phase 2 · registry result, not featured evidence · combination
5%1500 mg + 750 mg
NCT03794544 · Phase 2 · registry result, not featured evidence · combination
14.3%1500 mg + 3000 mg
NCT03794544 · Phase 2 · registry result, not featured evidence · combination
78.3%Arm A: BI 1361849 mRNA Vaccine + D
NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination
91.2%Arm B: BI 1361849 mRNA Vaccine + D
NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination
7.1%Arm I (CLOSED) (Durvalumab and ACR
NCT03801902 · Phase 1 · registry result, not featured evidence
0%Arm II (CLOSED) (Durvalumab and St
NCT03801902 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT02125461 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 34 more results
—Sub-study A: Durvalumab
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
—Sub-study B: Durvalumab
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
—Sub-study B: Durvalumab+Tremelimum
NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
—
NCT03519971 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
—
NCT03164616 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
6%
NCT04416633 · Phase 4 · registry result, not featured evidence
—Arm A:Nivo + CCRT/Nivo + Ipi
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
—Arm B: Nivo + CCRT/Nivo
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
—
NCT04642469 · Phase 3 · registry result, not featured evidence
—
NCT04385368 · Phase 3 · registry result, not featured evidence · combination
—Cohort 1 (EGFR/ALK+)
NCT02087423 · Phase 2 · registry result, not featured evidence · combination
—Cohort 2
NCT02087423 · Phase 2 · registry result, not featured evidence
—Cohort 3 (TC >=90%)
NCT02087423 · Phase 2 · registry result, not featured evidence
—Durvalumab Cohort A: Standard Radi
NCT04249362 · Phase 2 · registry result, not featured evidence
—Durvaumab Cohort B: Palliative Rad
NCT04249362 · Phase 2 · registry result, not featured evidence
—
NCT04003246 · Phase 2 · registry result, not featured evidence
—
NCT02572843 · Phase 2 · registry result, not featured evidence
—Arm A (Durvalumab + Oleclumab)
NCT03822351 · Phase 2 · registry result, not featured evidence · combination
—Arm B (Durvalumab + Monalizumab)
NCT03822351 · Phase 2 · registry result, not featured evidence · combination
—Durvalumab + Monalizumab
NCT03822351 · Phase 2 · registry result, not featured evidence · combination
—Durvalumab + Oleclumab
NCT03822351 · Phase 2 · registry result, not featured evidence · combination
—Durvalumab ECOG PS 0 or 1
NCT03693300 · Phase 2 · registry result, not featured evidence
—Durvalumab ECOG PS 2
NCT03693300 · Phase 2 · registry result, not featured evidence
—Arm 1 (Durvalumab Monotherapy)
NCT02904954 · Phase 2 · registry result, not featured evidence · monotherapy
—Arm 2 (Durvalumab Plus SBRT)
NCT02904954 · Phase 2 · registry result, not featured evidence · combination
—
NCT02879617 · Phase 2 · registry result, not featured evidence
—1500 mg
NCT03794544 · Phase 2 · registry result, not featured evidence
—1500 mg + 200 mg
NCT03794544 · Phase 2 · registry result, not featured evidence · combination
—1500 mg + 750 mg
NCT03794544 · Phase 2 · registry result, not featured evidence · combination
—1500 mg + 3000 mg
NCT03794544 · Phase 2 · registry result, not featured evidence · combination
4.3%Arm A: BI 1361849 mRNA Vaccine + D
NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination
11.8%Arm B: BI 1361849 mRNA Vaccine + D
NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination
—Arm I (CLOSED) (Durvalumab and ACR
NCT03801902 · Phase 1 · registry result, not featured evidence
—Arm II (CLOSED) (Durvalumab and St
NCT03801902 · Phase 1 · registry result, not featured evidence
Serious AEs
29.1%a
NCT02125461 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 34 more results
37.1%Sub-study A: Durvalumab
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
30.8%Sub-study B: Durvalumab
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
37.6%Sub-study B: Durvalumab+Tremelimum
NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
47%
NCT03519971 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
44.2%
NCT03164616 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
21%
NCT04416633 · Phase 4 · registry result, not featured evidence
63.8%Arm A:Nivo + CCRT/Nivo + Ipi
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
56.9%Arm B: Nivo + CCRT/Nivo
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
7.1%
NCT04642469 · Phase 3 · registry result, not featured evidence
31.1%
NCT04385368 · Phase 3 · registry result, not featured evidence · combination
16.2%Cohort 1 (EGFR/ALK+)
NCT02087423 · Phase 2 · registry result, not featured evidence · combination
29.1%Cohort 2
NCT02087423 · Phase 2 · registry result, not featured evidence
35.3%Cohort 3 (TC >=90%)
NCT02087423 · Phase 2 · registry result, not featured evidence
43.4%Durvalumab Cohort A: Standard Radi
NCT04249362 · Phase 2 · registry result, not featured evidence
36.7%Durvaumab Cohort B: Palliative Rad
NCT04249362 · Phase 2 · registry result, not featured evidence
70%
NCT04003246 · Phase 2 · registry result, not featured evidence
53.7%
NCT02572843 · Phase 2 · registry result, not featured evidence
—Arm A (Durvalumab + Oleclumab)
NCT03822351 · Phase 2 · registry result, not featured evidence · combination
—Arm B (Durvalumab + Monalizumab)
NCT03822351 · Phase 2 · registry result, not featured evidence · combination
27.9%Durvalumab + Monalizumab
NCT03822351 · Phase 2 · registry result, not featured evidence · combination
33.9%Durvalumab + Oleclumab
NCT03822351 · Phase 2 · registry result, not featured evidence · combination
28.1%Durvalumab ECOG PS 0 or 1
NCT03693300 · Phase 2 · registry result, not featured evidence
0%Durvalumab ECOG PS 2
NCT03693300 · Phase 2 · registry result, not featured evidence
40%Arm 1 (Durvalumab Monotherapy)
NCT02904954 · Phase 2 · registry result, not featured evidence · monotherapy
50%Arm 2 (Durvalumab Plus SBRT)
NCT02904954 · Phase 2 · registry result, not featured evidence · combination
55.3%
NCT02879617 · Phase 2 · registry result, not featured evidence
11.5%1500 mg
NCT03794544 · Phase 2 · registry result, not featured evidence
31.3%1500 mg + 200 mg
NCT03794544 · Phase 2 · registry result, not featured evidence · combination
5%1500 mg + 750 mg
NCT03794544 · Phase 2 · registry result, not featured evidence · combination
9.5%1500 mg + 3000 mg
NCT03794544 · Phase 2 · registry result, not featured evidence · combination
60.9%Arm A: BI 1361849 mRNA Vaccine + D
NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination
64.7%Arm B: BI 1361849 mRNA Vaccine + D
NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination
46.2%Arm I (CLOSED) (Durvalumab and ACR
NCT03801902 · Phase 1 · registry result, not featured evidence
41.7%Arm II (CLOSED) (Durvalumab and St
NCT03801902 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
a
cough 35.6% (placebo 25.2%)
fatigue 24% (placebo 20.1%)
dyspnoea 22.3% (placebo 24.4%)
NCT02125461 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 32 more results
decreased appetite 25.8%
constipation 21%
cough 17.7%
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
decreased appetite 23.1%
diarrhoea 21.4%
fatigue 18.8%
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
diarrhoea 20.8%
decreased appetite 19.7%
asthenia 17.9%
NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
anaemia 41.1% (placebo 37%)
neutropenia 26.9% (placebo 25.9%)
nausea 25.1% (placebo 24.1%)
NCT03519971 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
anaemia 45.5%
nausea 41.2%
neutropenia 29.7%
NCT03164616 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
cough 20%
pyrexia 19%
dyspnoea 13%
NCT04416633 · Phase 4 · registry result, not featured evidence
anaemia 44%
nausea 34.8%
constipation 29.1%
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
anaemia 41.5%
nausea 32.7%
cough 26.1%
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
hypothyroidism 28.6% (placebo 0%)
asthenia 21.4% (placebo 0%)
pruritus 21.4% (placebo 0%)
NCT04642469 · Phase 3 · registry result, not featured evidence
nausea 42.2% (placebo 40.9%)
anaemia 33.3% (placebo 27.3%)
fatigue 33.3% (placebo 27.3%)
NCT04385368 · Phase 3 · registry result, not featured evidence · combination
cough 23.4%
decreased appetite 13.5%
fatigue 13.5%
NCT02087423 · Phase 2 · registry result, not featured evidence · combination
decreased appetite 26.8%
fatigue 26%
cough 21.1%
NCT02087423 · Phase 2 · registry result, not featured evidence
fatigue 29.4%
constipation 23.5%
cough 19.1%
NCT02087423 · Phase 2 · registry result, not featured evidence
anaemia 24.5%
asthenia 24.5%
dyspnoea 20.8%
NCT04249362 · Phase 2 · registry result, not featured evidence
cough 24.5%
constipation 20.4%
fatigue 20.4%
NCT04249362 · Phase 2 · registry result, not featured evidence
weight loss 80%
anorexia 70%
fatigue 70%
NCT04003246 · Phase 2 · registry result, not featured evidence
fatigue 68.7%
nausea 67.2%
diarrhea 62.7%
NCT02572843 · Phase 2 · registry result, not featured evidence
cough 42.6%
asthenia 24.6%
pruritus 24.6%
NCT03822351 · Phase 2 · registry result, not featured evidence · combination
cough 32.2%
dyspnoea 25.4%
asthenia 18.6%
NCT03822351 · Phase 2 · registry result, not featured evidence · combination
cough 37.7%
asthenia 25.4%
dyspnoea 23.7%
NCT03693300 · Phase 2 · registry result, not featured evidence
asthenia 66.7%
cough 66.7%
dyspnoea 66.7%
NCT03693300 · Phase 2 · registry result, not featured evidence
constipation 66.7%
fatigue 60%
cough 43.3%
NCT02904954 · Phase 2 · registry result, not featured evidence · monotherapy
constipation 70%
anemia 53.3%
fatigue 46.7%
NCT02904954 · Phase 2 · registry result, not featured evidence · combination
anemia 63.8%
hypoalbuminemia 55.3%
lymphocyte count decreased 48.9%
NCT02879617 · Phase 2 · registry result, not featured evidence
1500 mg
fatigue 23.1%
procedural pain 19.2%
asthenia 11.5%
NCT03794544 · Phase 2 · registry result, not featured evidence
1500 mg + 200 mg
dyspnoea 18.8%
fatigue 18.8%
alanine aminotransferase increased 12.5%
NCT03794544 · Phase 2 · registry result, not featured evidence · combination
1500 mg + 750 mg
constipation 10%
fatigue 10%
pruritus 10%
NCT03794544 · Phase 2 · registry result, not featured evidence · combination
1500 mg + 3000 mg
fatigue 19%
asthenia 14.3%
cough 14.3%
NCT03794544 · Phase 2 · registry result, not featured evidence · combination
decreased appetite 34.8%
fatigue 34.8%
anaemia 30.4%
NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination
cough 35.3%
fatigue 32.4%
nausea 32.4%
NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 92.3%
cough 76.9%
dyspnea 76.9%
NCT03801902 · Phase 1 · registry result, not featured evidence
dyspnea 75%
fatigue 75%
cough 66.7%
NCT03801902 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 29 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Durvalumab

PFS 16.8 vs 5.6 placebo months
time to event · months
NCT02125461 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 11 more results
3.8 vs 2.2 SoC months
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
3.5 vs 2.2 SoC months
NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
13.8 vs 9.4 placebo months
NCT03519971 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
6.2 vs 5.5 D + SoC months
NCT03164616 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
16.69 vs 15.64 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
16.82 vs 15.67 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
17.38 vs 15.67 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
16.82 vs 16.53 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
17.71 vs 16.53 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
21.1 vs 7.3 Durvalumab Monotherapy months
NCT03822351 · Phase 2 · registry result, not featured evidence · combination
19.8 vs 7.3 Durvalumab Monotherapy months
NCT03822351 · Phase 2 · registry result, not featured evidence · combination
Overall Survival NA vs 28.7 placebo months
time to event · months
NCT02125461 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 10 more results
11.7 vs 6.8 SoC months
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
11.5 vs 6.8 SoC months
NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
36.4 vs 29.5 placebo months
NCT03519971 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
14 vs 13.3 D + SoC months
NCT03164616 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
34.6 vs 39.79 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
39.49 vs 39.79 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
NA vs NA placebo months
NCT04385368 · Phase 3 · registry result, not featured evidence · combination
NA vs NA placebo months
NCT04385368 · Phase 3 · registry result, not featured evidence · combination
NA vs 40.9 Durvalumab Monotherapy months
NCT03822351 · Phase 2 · registry result, not featured evidence · combination
NA vs 40.9 Durvalumab Monotherapy months
NCT03822351 · Phase 2 · registry result, not featured evidence · combination
ORR 30% (n=443) vs 17.8% (n=213) placebo
absolute value · percentage points
NCT02125461 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
46.3% (n=335) vs 48.5% (n=330) D + SoC
NCT03164616 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Duration of Response NA vs 18.4 placebo months
time to event · months
NCT02125461 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 11 more results
9.5 vs 4.8 SoC months
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
12.2 vs 4.8 SoC months
NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
10 vs 4.8 SoC months
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
30.7 vs 18.6 placebo months
NCT03519971 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
7.4 vs 6 D + SoC months
NCT03164616 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
25.76 vs 25.17 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
31.84 vs 25.17 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
22.83 vs 27.93 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
33.18 vs 27.93 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
29.9 vs NA Durvalumab Monotherapy months
NCT03822351 · Phase 2 · registry result, not featured evidence · combination
23 vs NA Durvalumab Monotherapy months
NCT03822351 · Phase 2 · registry result, not featured evidence · combination
PFS12 55.9% (n=476) vs 35.3% (n=237) placebo @ 52wk
absolute value · percentage points
NCT02125461 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
PFS18 44.2% (n=476) vs 27% (n=237) placebo @ 78wk
absolute value · percentage points
NCT02125461 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Time to Death or Distant Metastasis 28.3 vs 16.2 placebo months
time to event · months
NCT02125461 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 3 more results
51 vs 46.3 placebo months
NCT03519971 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
30.65 vs 30.36 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
36.14 vs 30.36 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
OS24 66.3% (n=476) vs 55.6% (n=237) placebo @ 104wk
absolute value · percentage points
NCT02125461 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
PFS2 28.3 vs 17.1 placebo months
time to event · months
NCT02125461 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 4 more results
9.1 vs 6.7 SoC months
NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
8 vs 6.7 SoC months
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
27.8 vs 22 placebo months
NCT03519971 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
10.4 vs 10.2 D + SoC months
NCT03164616 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Overall Survival 11.5 months
time to event · months
No placebo or comparator arm
NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 14 more results
10 months
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
13.3 months
NCT02087423 · Phase 2 · registry result, not featured evidence · combination
9.9 months
NCT02087423 · Phase 2 · registry result, not featured evidence · combination
10.9 months
NCT02087423 · Phase 2 · registry result, not featured evidence · combination
9.3 months
NCT02087423 · Phase 2 · registry result, not featured evidence · combination
13.2 months
NCT02087423 · Phase 2 · registry result, not featured evidence
21.1 months
NCT04249362 · Phase 2 · registry result, not featured evidence
16.8 months
NCT04249362 · Phase 2 · registry result, not featured evidence
15.97 months*
NCT04003246 · Phase 2 · registry result, not featured evidence · converted to months from 486 days as posted
39 months
NCT03693300 · Phase 2 · registry result, not featured evidence
12.3 months
NCT03693300 · Phase 2 · registry result, not featured evidence
6 months
NCT02879617 · Phase 2 · registry result, not featured evidence
23.5 months
NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination
7.5 months
NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination
OS Rate at 12 49.3% (n=62) vs 31.3% (n=64) SoC @ 48wk
responder rate · % of participants
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 3 more results
49.5% (n=174) vs 31.3% (n=64) SoC @ 48wk
NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
43.6% (n=117) vs 31.3% (n=64) SoC @ 48wk
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
58.4% (n=219) vs 59.5% (n=109) placebo @ 104wk
NCT03519971 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
PFS 3.5 months
time to event · months
No placebo or comparator arm
NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 12 more results
3.1 months
NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
10.3 months
NCT04249362 · Phase 2 · registry result, not featured evidence
7.6 months
NCT04249362 · Phase 2 · registry result, not featured evidence
13.1 months
NCT03693300 · Phase 2 · registry result, not featured evidence
3.7 months
NCT03693300 · Phase 2 · registry result, not featured evidence
3 months
NCT02879617 · Phase 2 · registry result, not featured evidence
2 months
NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination
1.8 months
NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination
2 months
NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination
1.8 months
NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination
20.4 months
NCT03801902 · Phase 1 · registry result, not featured evidence
30.2 months
NCT03801902 · Phase 1 · registry result, not featured evidence

+ 49 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Durvalumab's landscape · Tagitanlimab's landscape